Shots:
- The US Early Feasibility Study assessed TTVR system in 22 pts with severe to torrential tricuspid regurgitation; enrollment in the trans-jugular cohort is complete, with the study continuing via Trisol’s newly developed trans-femoral access route
- Safety outcomes showed <5% permanent pacemaker need at 30 days, with considerable reduction in tricuspid regurgitation following implantation
- At 30 days & 12mos. follow-up, pts demonstrated improved QoL (KCCQ), NYHA class, 6-minute walk distance, right ventricular function & cardiac output, alongside successful device deployment with no migration
Ref: PRnewswire | Image: Trisol Medical | Press Release
Related News: BD’s EnCor EnCompass System Secures the US FDA 510(k) Clearance for Breast Biopsy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
